tirzepatide and water retention Hydration on Tirzepatide: Intake Guide Tirzepatide | PeterMD

In a randomised, placebo-controlled double blinded phase 1 study of ascending single doses in healthy overweight humans, cotadutide was shown to be safe and, in common with the GLP-1 analogues, to be associated with dose-dependent gastrointestinal adverse events especially nausea and vomiting

J Diabetes 2025;17:e70082

But weight management is the core business, and it is the reason most people encounter the brand

In comparison, a multicenter clinical trial on IGB use reported a total body weight loss of 8.5% at 3 months, 11.8% at 6 months, and 13.3% at 12 months, while semaglutide studies have shown approximately 10.9% weight loss at 6 months and 13.9% at 12 months [12, 13]

This first-of-its-kind analysis is a step toward understanding how peer support fits into the bipolar disorder treatment landscape